Lars Vibe Andreasen1, Lasse Bøllehuus Hansen2, Peter Andersen2, Else Marie Agger2, Jes Dietrich3. 1. Department of Vaccine Development, Statens Serum Institut, Copenhagen, Denmark. 2. Department of Infectious Disease Immunology, Statens Serum Institut, Copenhagen, Denmark. 3. Department of Infectious Disease Immunology, Statens Serum Institut, Copenhagen, Denmark. Electronic address: jdi@ssi.dk.
Abstract
BACKGROUND: The development of new low cost inactivated polio virus based vaccines (IPV) is a high priority and will be essential for the complete eradication of polio. Since the aluminium hydroxide adjuvant is widely used in humans we tested this adjuvant with IPV in two models. Our objective was twofold; to examine the IPV dose sparing effect of aluminium hydroxide and how the adjuvant effect of aluminium hydroxide affected the immunity induced by IPV. METHODS: Mice and rats were immunized with IPV formulated with Aluminium hydroxide and subjected to immunological analyses and serum polio virus neutralization titer determination. RESULTS: Addition of aluminium hydroxide to IPV led to a ten times dose sparing effect compared to IPV alone, measured by virus neutralization titers in serum. Aluminium hydroxide changed the kinetics of the response against IPV leading to a faster and stronger response, which due to IPV induced immune dominance was characterized as a strong Th1-biased cellular/humoral immune response. CONCLUSIONS: The IPV-aluminium hydroxide formulation constitutes a promising vaccine capable of generating strong Th1 immunity against infection with all three serotypes. A phase I/II clinical study was recently initiated.
BACKGROUND: The development of new low cost inactivated polio virus based vaccines (IPV) is a high priority and will be essential for the complete eradication of polio. Since the aluminium hydroxide adjuvant is widely used in humans we tested this adjuvant with IPV in two models. Our objective was twofold; to examine the IPV dose sparing effect of aluminium hydroxide and how the adjuvant effect of aluminium hydroxide affected the immunity induced by IPV. METHODS:Mice and rats were immunized with IPV formulated with Aluminium hydroxide and subjected to immunological analyses and serum polio virus neutralization titer determination. RESULTS: Addition of aluminium hydroxide to IPV led to a ten times dose sparing effect compared to IPV alone, measured by virus neutralization titers in serum. Aluminium hydroxide changed the kinetics of the response against IPV leading to a faster and stronger response, which due to IPV induced immune dominance was characterized as a strong Th1-biased cellular/humoral immune response. CONCLUSIONS: The IPV-aluminium hydroxide formulation constitutes a promising vaccine capable of generating strong Th1 immunity against infection with all three serotypes. A phase I/II clinical study was recently initiated.
Authors: David A Muller; Frances E Pearson; Germain J P Fernando; Christiana Agyei-Yeboah; Nick S Owens; Simon R Corrie; Michael L Crichton; Jonathan C J Wei; William C Weldon; M Steven Oberste; Paul R Young; Mark A F Kendall Journal: Sci Rep Date: 2016-02-25 Impact factor: 4.379
Authors: Christopher B Fox; Mark T Orr; Neal Van Hoeven; Sarah C Parker; Traci J T Mikasa; Tony Phan; Elyse A Beebe; Ghislain I Nana; Sharvari W Joshi; Mark A Tomai; James Elvecrog; Timothy R Fouts; Steven G Reed Journal: J Control Release Date: 2016-11-12 Impact factor: 9.776
Authors: Line M Lindgren; Pernille N Tingskov; Annette H Justesen; Bettina S Nedergaard; Klaus J Olsen; Lars V Andreasen; Ingrid Kromann; Charlotte Sørensen; Jes Dietrich; Birgit Thierry-Carstensen Journal: Vaccine Date: 2016-12-24 Impact factor: 3.641
Authors: Luis Rivera; Rasmus S Pedersen; Lourdes Peña; Klaus J Olsen; Lars V Andreasen; Ingrid Kromann; Pernille I Nielsen; Charlotte Sørensen; Jes Dietrich; Ananda S Bandyopadhyay; Birgit Thierry-Carstensen Journal: Lancet Infect Dis Date: 2017-04-25 Impact factor: 25.071
Authors: Lulu C Bravo; Josefina C Carlos; Salvacion R Gatchalian; May Emmeline B Montellano; Charissa Fay Corazon B Tabora; Birgit Thierry-Carstensen; Pernille Nyholm Tingskov; Charlotte Sørensen; Henrik Wachmann; Ananda S Bandyopadhyay; Pernille Ingemann Nielsen; Mie Vestergaard Kusk Journal: Vaccine Date: 2019-11-05 Impact factor: 3.641
Authors: David A Muller; Germain J P Fernando; Nick S Owens; Christiana Agyei-Yeboah; Jonathan C J Wei; Alexandra C I Depelsenaire; Angus Forster; Paul Fahey; William C Weldon; M Steven Oberste; Paul R Young; Mark A F Kendall Journal: Sci Rep Date: 2017-10-03 Impact factor: 4.379